
Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

Memo Therapeutics and Ono Pharmaceutical enter partnership
Under the terms of the agreement, Memo Therapeutics AG will leverage its microfluidic single-cell molecular cloning and screening technologies to...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

Growing investor interest in biotechnology
Institutional investors and financial analysts reported at the German Equity Forum that the biotech sector has become significantly more attractive....

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...

BioNTech bags Instadeep for £562m
According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...